> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# EUA for Vir/GSK Covid Antibody Treatment
- URL: https://www.fdaweb.com/eua-for-vir-gsk-covid-antibody-treatment/
- Published: 2021-05-27T12:00:00.000Z
- Updated: 2026-09-14T17:00:49.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149420

FDA has approved an emergency use authorization for a monoclonal antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate Covid-19 in those age 12 and over. FDA [said](https://www.marketwatch.com/story/glaxosmithkline-and-vir-win-fda-emergency-authorization-for-covid-antibody-treatment-in-adults-and-children-2021-05-27?ref=fdaweb.com) the drug, Sotrovimab, is not authorized for patients who are hospitalized due to Covid-19 or require oxygen therapy.

The companies say the treatment will be available in the coming weeks and they plan to submit a marketing application to FDA in the second half of the year.